Back to Journals » Open Access Journal of Clinical Trials » Volume 1 » Default

Biomarker discovery in neurological diseases: a metabolomic approach

Authors El-Ansary A, Al-Afaleg N, Al-Yafaee Y

Published 1 December 2009 Volume 2009:1(Default) Pages 27—41

DOI https://doi.org/10.2147/OAJCT.S7746

Review by Single-blind

Peer reviewer comments 2


Afaf El-Ansary, Nouf Al-Afaleg, Yousra Al-Yafaee

Biochemistry Department, Science College, King Saud University, Riyadh, Saudi Arabia

Abstract: Biomarkers are pharmacological and physiological measurements or specific biochemicals in the body that have a particular molecular feature that makes them useful for measuring the progress of disease or the effects of treatment. Due to the complexity of neurological disorders, it is very difficult to have perfect markers. Brain diseases require plenty of markers to reflect the metabolic impairment of different brain cells. The recent introduction of the metabolomic approach helps the study of neurological diseases based on profiling a multitude of biochemical components related to brain metabolism. This review is a trial to elucidate the possibility to use this approach to identify plasma metabolic markers related to neurological disorders. Previous trials using different metabolomic analyses including nuclear magnetic resonance spectroscopy, gas chromatography combined with mass spectrometry, liquid chromatography combined with mass spectrometry, and capillary electrophoresis will be traced.

Keywords: metabolic biomarkers, neurological disorders. metabolome, nuclear magnetic resonance, mass spectrometry, chromatography

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]